Loading
institutionsInstitution
Samsung Medical Center
Samsung Medical Center in Seoul is Korea's highest-ranked cancer hospital and one of Asia's largest enrolling sites for lung, gastric and breast antibody-drug conjugate trials; it also runs a proton therapy centre. How far its largely Korean trial results generalise to other regions is a question regulators keep asking.
Overview
Samsung Medical Center in Seoul is Korea's highest-ranked cancer hospital, placed third in the Newsweek/Statista World's Best Specialized Hospitals list for oncology, and home to the Samsung Comprehensive Cancer Center. It matters to global drug development because it is a leading enroller in non-small-cell lung cancer, gastric cancer and breast antibody-drug conjugate trials, and it operates a proton therapy centre. OnCo links it to gastric and gastro-oesophageal junction cancer, to the DeLLphi-301 tarlatamab paper in small-cell lung cancer, to the Korean Cancer Study Group and to clinicians including Jeeyun Lee, Won Ki Kang and Woong-Yang Park. How far results from its largely Korean trial populations generalise to other regions is an open question that regulators keep asking. Its lung and gastric programmes are the ones to follow.
Location
Seoul, KR
Type
hospital
Website
Newsweek 2026 oncology rank
#3
OnCo score
#30 · 75 points (57 Newsweek + 0 NCI + 18 from 9 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Samsung Medical Center, including child institutions. 1,319 works · 17,459 citations · 73% open access · 15% clinical trials · 1% reviews.
Oncology works per year
2612022
3042023
2822024
2622025
2102026
Most works
- Myung‐Ju Ahn74 works
- Se‐Hoon Lee71 works
- In Woong Han62 works
- Jin Seok Ahn60 works
- Sang Hyun Shin54 works
- Jin Seok Heo47 works
- So Jeong Yoon43 works
- Jeeyun Lee42 works
- Hyun Ae Jung42 works
- Yeon Hee Park39 works
Most cited
- Lung cancer trials
- Gastric cancer
- Proton therapy
Ho Yeong Lim
Professor of Medical Oncology; hepatocellular carcinoma
Hepatocellular carcinomaSystemic therapyClinical trials
A liver cancer oncologist who has been on the steering group of several global HCC trials with strong Asian enrolment.
Jeeyun Lee
Professor of Medical Oncology; gastrointestinal cancer and precision oncology
Gastric cancerPrecision oncologyMolecular profiling
A gastric cancer trialist who pioneered biomarker-driven umbrella trials in Korea and helped bring HER2 and Claudin 18.2 agents to Asian patients.
Jong-Mu Sun
Medical oncologist, Samsung Medical Center, Seoul
Oesophageal cancerLung cancerImmunotherapy
Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer.
Keunchil Park
Medical oncologist and trial lead, Samsung Medical Center, Seoul
EGFR-mutant lung cancerBispecific antibodiesEarly-phase trials
Korean lung cancer specialist who led CHRYSALIS, the first human study of amivantamab, whose exon 20 insertion cohort earned the drug its first approval.
Myung-Ju Ahn
Professor, Division of Hematology-Oncology; thoracic and head-and-neck medical oncology
Lung cancerHead and neck cancerTargeted therapy
Myung-Ju Ahn is one of Asia's most prolific lung cancer trialists, a steady presence on the steering committees of the EGFR, ALK, and immunotherapy trials that set today's standards.
Won Ki Kang
Professor of Medical Oncology; gastrointestinal oncology
Gastric cancerAdjuvant chemotherapyClinical trials
A senior gastric cancer oncologist whose adjuvant and perioperative trials in Korea helped define post-gastrectomy chemotherapy.
Woong-Yang Park
Director, Samsung Genome Institute; Professor of Molecular Cell Biology
Cancer genomicsSingle-cell sequencingPrecision oncology platforms
Built the genome institute behind Samsung Medical Center's precision oncology programme and its single-cell studies of tumours.
Yeon Hee Park
Professor of Medical Oncology; breast cancer programme
Breast cancerHER2-positive diseaseYoung-onset breast cancer
Leads breast medical oncology at Samsung Medical Center and has driven Korean participation in the HER2 and CDK4/6 trials that changed practice.
Similar pages
- InstitutionChang Gung Memorial Hospital
Shares Sumitomo Heavy Industries, Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy.
- InstitutionSeoul National University Hospital
Shares Korean Cancer Study Group, Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Gastric & gastro-oesophageal junction cancer.
- InstitutionSeverance Hospital, Yonsei University
Shares Korean Cancer Study Group, Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS).
- TechnologyAccelerator-based BNCT systems (NeuCure, nuBeam, NeuPex)
Shares Sumitomo Heavy Industries, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Proton therapy machines: cyclotrons, synchrotrons and single-room systems.
- InstitutionApollo Hospitals (Apollo Cancer Centres)
Shares Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy.
- TrialCheckMate 649
Shares Won Ki Kang, Gastric & gastro-oesophageal junction cancer.
- InstitutionTaipei Veterans General Hospital
Shares Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Gastric & gastro-oesophageal junction cancer.
- InstitutionShizuoka Cancer Center
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, Gastric & gastro-oesophageal junction cancer.